Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
Malignant bowel obstruction is the cause of death in the majority of women who die of ovarian cancer. Some patients are considered acceptable surgical candidates for relief of the obstruction. For many patients, however, lack of such surgical options has spawned a broad range of medical interventions, including palliative strategies to target pain and nausea and vomiting. This review discusses the general approach to patients with ovarian cancer and inoperable malignant bowel obstruction, with an emphasis on such palliative strategies.
Jatoi
Aminah
A
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. jatoi.aminah@mayo.edu
Podratz
Karl C
KC
Gill
Paula
P
Hartmann
Lynn C
LC
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D013505:Digestive System Surgical Procedures; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007414:Intestinal Neoplasms / Q000150:complications* / Q000556:secondary; D007415:Intestinal Obstruction / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D015282:Octreotide / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000473:pathology*; D010166:Palliative Care / Q000379:methods; D011379:Prognosis; D015607:Stents; D014481:United States / Q000453:epidemiology
D000305:Adrenal Cortex Hormones; D000701:Analgesics, Opioid; D000932:Antiemetics; D018931:Antineoplastic Agents, Hormonal; D005765:Gastrointestinal Agents; D015282:Octreotide